北欧地区扩大≥65岁成人增强型流感疫苗接种项目预测可改善公共卫生与卫生系统韧性
该研究采用季节性流感决策树模型,比较北欧四国现行国家疫苗接种政策与≥65岁成人全覆盖增强型流感疫苗(EIV)项目的临床事件与成本。结果显示扩大EIV覆盖可分别预防瑞典、芬兰、挪威、丹麦13,929、6,411、5,951、2,438例有症状流感,并节省生命年与住院资源。结论认为疫苗采购增加的预算相对于整体医疗支出属低成本投资。
要点
- 北欧四国扩大≥65岁EIV覆盖可预防有症状流感并节省生命年。
- 扩大EIV覆盖可减少住院和住院日,提升卫生系统韧性。
- 疫苗采购额外预算相对整体医疗支出属低成本投资。
核心结论
- 扩大EIV项目至所有≥65岁成人可带来显著公共卫生收益,疫苗采购增加的预算相对整体医疗支出属低成本投资。
研究设计与样本
- 研究开发季节性流感决策树模型,估计有症状感染及后续并发症,并用疫苗有效性调整有症状感染风险。
- 比较各国国家疫苗接种政策与≥65岁成人EIV项目,疫苗有效性和临床概率来自已发表研究,成本按各国本地数据推算。
主要发现
- 扩大EIV覆盖至所有≥65岁成人预测可预防有症状流感:瑞典13,929例、芬兰6,411例、挪威5,951例、丹麦2,438例。
- 由避免的有症状感染估计节省生命年:瑞典1,615、芬兰804、挪威762、丹麦407。
- 估计减少住院例数:瑞典786、芬兰362、挪威336、丹麦138;减少住院日:瑞典6,511、芬兰2,997、挪威2,782、丹麦1,140。
临床怎么用
- 在北欧地区,可考虑将EIV项目扩大至所有≥65岁成人,以预防有症状流感、减少住院并节省生命年。
- 决策时可参考各国预测的临床事件减少数与疫苗采购额外预算,结合整体医疗支出评估投资合理性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza continues to pose a significant recurring challenge for public health and healthcare systems. Influenza infection can cause short-term complications leading to hospitalisations, or death, and may require post-discharge care at home or in nursing facilities. Additionally, the economic burden of influenza is substantial and impacts healthcare resources and budgets. Enhanced influenza vaccines (EIV) have been shown to provide better protection against influenza infection and downstream clinical outcomes. However, access to EIVs remains limited for older adults in the Nordic region. This study predicted clinical events and associated costs that could be saved by investing in enhanced influenza vaccine for all adults aged ≥65. METHODS: A seasonal influenza model was developed as a decision tree, estimating symptomatic infections and following complications and modifying the risk of symptomatic infection with the vaccine effectiveness. National vaccination policies were compared with an EIV program for adults aged ≥65 years. Vaccine effectiveness and clinical probabilities were informed by published studies and costs were derived for each country. RESULTS: For Sweden, Finland, Norway, and Denmark expanding EIV coverage programmes to cover all ≥65-year-olds was predicted to prevent 13,929; 6411; 5951; and 2438 symptomatic influenza cases, respectively. From these averted symptomatic infections, an estimated 1615; 804; 762; 407 life-years were subsequently saved. The estimated reductions in hospitalisation and hospital days were: 786 and 6511; 362 and 2997; 336 and 2782; and 138 and 1140, respectively. The estimated additional budget impact due to vaccine acquisition costs was estimated at €7.7 million in Sweden, €2.5 million in Finland, €4.4 million in Norway, and €2.4 million in Denmark for extending EIV coverage to adults aged ≥65. CONCLUSIONS: Estimated increases in overall healthcare spending associated with expanding EIV programmes could be a low-cost investment in the light of overall healthcare expenditure, considering the substantial gains in public health and healthcare system resilience.
引用
- Grootendorst A, Paludan-Müller AS, Madsen K, et al. Expanding enhanced influenza vaccines programs for adults aged ≥65 in the Nordic region predicted to improve public health and health system resilience. Vaccine. 2026. PMID: 42468224. doi:10.1016/j.vaccine.2026.128934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。